International Edition
Latest News
Technology

Exon-Skipping Therapies Improve Clinical and Molecular Outcomes in DMD, Systematic Review Finds

Nine randomized controlled trials published between January 2016 and December 2024 form the basis of a systematic review evaluating exon-skipping therapies for Duchenne muscular dystrophy, DocWireNews reported. Researchers examined the efficacy and safety of treatments for the X-linked…

Exon-Skipping Therapies Improve Clinical and Molecular Outcomes in DMD, Systematic Review Finds

Nine randomized controlled trials published between January 2016 and December 2024 form the basis of a systematic review evaluating exon-skipping therapies for Duchenne muscular dystrophy, DocWireNews reported.

Researchers examined the efficacy and safety of treatments for the X-linked recessive disorder, which causes progressive muscle weakness and muscle wasting. The evaluation covers trials investigating targeted genetic interventions across international medical centers in seven different countries, according to data published in the European Journal of Medical Genetics.

Four of the analyzed studies evaluated viltolarsen for exon 53 skipping, three utilized eteplirsen for exon 51, and two assessed golodirsen for exon 53. Trial lengths varied significantly, showing an average length of 119.6 weeks with a standard deviation of 78.5 weeks, as noted in PubMed records.

Patients receiving the exon-skipping medications showed measurable improvements in primary clinical outcomes. These metrics included performance on the 6-minute walking test, time to stand, and the North Star Ambulatory Assessment.

Biological measurements gathered during the research indicated concurrent increases in dystrophin expression and overall exon skipping percentage. Long-term follow-up data demonstrated that patients achieved stabilization in both clinical and molecular outcomes when compared directly against age- and treatment-matched controls.

Comparison between the individual trials remained impossible due to heterogeneity in study designs. This variation prevented the authors from directly contrasting outcomes between different exon-skipping therapies.

The authors concluded that the findings serve as an important stepping stone toward developing novel exon-skipping precision therapies. However, they emphasized that longer follow-up extension studies are required to better understand the long-term effects of these treatments in patients with Duchenne muscular dystrophy.

The review also identified several methodological limitations, including small sample sizes and a lack of variant-matched or placebo control groups across the evaluated literature.

About the author: Technology Desk

Technology Desk at Archynewsy.